Tearsheet

argenx (ARGX)

Market Price (9/4/2025): $720.99 | Market Cap: $44.0 Bil
Sector: Health Care | Industry: Biotechnology

argenx (ARGX)

Market Price (9/4/2025): $720.99
Market Cap: $44.0 Bil
Sector: Health Care
Industry: Biotechnology

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$720.99	$615.00	$380.43	$378.83	$350.19
Market Cap CYE ($ Bil)	44.0	37.2	22.5	21.0	18.0
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	3.4	3.2	2.2	2.3
Enterprise Value ($ Bil)	0.0	37.2	22.5	21.0	18.0
Valuation Ratios
P/S TTM	17.0	16.8	17.7	50.2	36.0
P/EBIT TTM	120.5	420.0	-71.6	-28.3	-44.9
P/E TTM	41.3	44.2	-73.7	-29.0	-43.8
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$720.99	$615.00	$380.43
Market Cap CYE ($ Bil)	44.0	37.2	22.5
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	3.4	3.2
Enterprise Value ($ Bil)	0.0	37.2	22.5
Valuation Ratios
P/S TTM	17.0	16.8	17.7
P/EBIT TTM	120.5	420.0	-71.6
P/E TTM	41.3	44.2	-73.7
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ARGX Return	83%	19%	8%	0%	62%	17%	320%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ABBV, AMGN, GILD, REGN.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Day 11 of Gains Streak for argenx Stock with 22% Return (vs. 12% YTD) [8/4/2025]	Notification
2	Stacking Up ARGX Against Its Peers - Is It Still a Buy?
3	As ARGX Surges 14% in a Week, PTCT's Story Stands Out	Counter-Intuitive Comparisons
4	Day 10 of Gains Streak for argenx Stock with 19% Return (vs. 9.6% YTD) [8/1/2025]	Notification
5	Day 9 of Gains Streak for argenx Stock with 19% Return (vs. 9% YTD) [7/31/2025]	Notification
6	ARGX Dip Buy Analysis
7	argenx (ARGX) Valuation Ratios Comparison	Financials
8	argenx Total Shareholder Return (TSR): 61.7% in 2024 and 20.6% 3-yr compounded annual returns (above peer average)
9	argenx (ARGX) Operating Cash Flow Comparison	Financials
10	argenx (ARGX) Net Income Comparison	Financials
11	ARTICLES
12	ARGX Stock Up 22% after 11-Day Win Streak		August 5th, 2025
13	ARGX Stock in Focus: Does It Outshine the Peer Group?		August 2nd, 2025
14	Big Move for ARGX, but Do PTCT’s Margins and Growth Give It the Edge?		August 2nd, 2025
15	ARGX Stock Up 19% after 10-Day Win Streak		August 2nd, 2025
16	ARGX Stock Up 19% after 9-Day Win Streak		August 1st, 2025

	Title
0	DASHBOARDS
1	ARGX Stock Up 22% after 11-Day Win Streak
2	ARGX Stock in Focus: Does It Outshine the Peer Group?
3	Big Move for ARGX, but Do PTCT’s Margins and Growth Give It the Edge?
4	ARGX Stock Up 19% after 10-Day Win Streak
5	ARGX Stock Up 19% after 9-Day Win Streak
6	ARTICLES
7	Day 11 of Gains Streak for argenx Stock with 22% Return (vs. 12% YTD) [8/4/2025]
8	Stacking Up ARGX Against Its Peers - Is It Still a Buy?
9	As ARGX Surges 14% in a Week, PTCT's Story Stands Out
10	Day 10 of Gains Streak for argenx Stock with 19% Return (vs. 9.6% YTD) [8/1/2025]
11	Day 9 of Gains Streak for argenx Stock with 19% Return (vs. 9% YTD) [7/31/2025]
12	ARGX Dip Buy Analysis
13	argenx (ARGX) Valuation Ratios Comparison
14	argenx Total Shareholder Return (TSR): 61.7% in 2024 and 20.6% 3-yr compounded annual returns (above peer average)
15	argenx (ARGX) Operating Cash Flow Comparison
16	argenx (ARGX) Net Income Comparison

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for argenx

Financials

	ARGX	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	argenx	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Price	-	401.00	211.92	286.92	112.71	577.90	286.92
Mkt Cap	-	102.9	374.7	154.4	140.3	60.7	140.3
Rev LTM	-	11,419	58,328	34,917	28,862	14,214	28,862
Op Inc LTM	-	-199	13,695	8,192	10,797	3,841	8,192
FCF LTM	-	3,500	18,239	10,605	9,369	3,556	9,369
FCF 3Y Avg	-	1,984	20,273	8,590	8,397	3,248	8,397
CFO LTM	-	3,846	19,283	12,013	9,868	4,744	9,868
CFO 3Y Avg	-	2,324	21,154	9,753	8,949	4,518	8,949

Growth & Margins

	ARGX	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	argenx	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Rev Chg LTM	-	10.5%	6.1%	12.9%	3.8%	5.4%	6.1%
Rev Chg 3Y Avg	-	11.0%	0.6%	10.0%	1.6%	0.3%	1.6%
Rev Chg Q	-	12.1%	6.6%	9.4%	1.8%	3.6%	6.6%
QoQ Delta Rev Chg LTM	-	2.9%	1.7%	2.3%	0.4%	0.9%	1.7%
Op Mgn LTM	-	-1.7%	23.5%	23.5%	37.4%	27.0%	23.5%
Op Mgn 3Y Avg	-	26.5%	27.2%	26.4%	39.2%	30.1%	27.2%
QoQ Delta Op Mgn LTM	-	2.0%	1.0%	1.6%	-0.0%	-0.2%	1.0%
CFO/Rev LTM	-	33.7%	33.1%	34.4%	34.2%	33.4%	33.7%
CFO/Rev 3Y Avg	-	22.5%	37.5%	32.0%	31.9%	33.6%	32.0%
FCF/Rev LTM	-	30.6%	31.3%	30.4%	32.5%	25.0%	30.6%
FCF/Rev 3Y Avg	-	19.2%	36.0%	28.2%	30.0%	24.1%	28.2%

Valuation

	ARGX	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	argenx	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Cap	-	102.9	374.7	154.4	140.3	60.7	140.3
P/S	-	9.0	6.4	4.4	4.9	4.3	4.9
P/EBIT	-	23.4	63.6	14.9	17.1	12.4	17.1
P/E	-	28.3	99.6	23.3	22.2	13.6	23.3
P/CFO	-	26.8	19.4	12.8	14.2	12.8	14.2
Total Yield	-	3.5%	4.0%	7.5%	7.3%	7.6%	7.3%
Dividend Yield	-	0.0%	3.0%	3.2%	2.8%	0.3%	2.8%
FCF Yield 3Y Avg	-	2.1%	7.3%	6.2%	8.0%	4.4%	6.2%
D/E	-	0.0	0.2	0.4	0.2	0.0	0.2
Net D/E	-	-0.0	0.2	0.3	0.1	-0.1	0.1

Returns

	ARGX	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	argenx	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
1M Rtn	-	-13.2%	8.6%	-2.6%	-0.4%	3.6%	-0.4%
3M Rtn	-	-10.2%	14.2%	-0.1%	3.8%	18.6%	3.8%
6M Rtn	-	-17.5%	3.8%	-6.5%	-0.4%	-14.2%	-6.5%
12M Rtn	-	-19.1%	11.8%	-11.2%	47.3%	-51.0%	-11.2%
3Y Rtn	-	42.7%	74.1%	30.3%	97.4%	-0.0%	42.7%
1M Excs Rtn	-	-16.1%	5.7%	-5.4%	-3.3%	0.7%	-3.3%
3M Excs Rtn	-	-18.1%	6.2%	-7.8%	-3.9%	9.8%	-3.9%
6M Excs Rtn	-	-26.7%	-7.7%	-15.8%	-11.1%	-25.0%	-15.8%
12M Excs Rtn	-	-32.8%	-2.4%	-24.7%	33.4%	-66.3%	-24.7%
3Y Excs Rtn	-	-15.1%	17.5%	-24.3%	45.4%	-56.7%	-15.1%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		3/20/2025	3/21/2024	3/16/2023	3/21/2022	3/30/2021	3/31/2020
Key Financials
Total Revenue	2,580	2,190	1,226	411	497	41	78
Ebitda	365	105	-192	-623	-393	-601	-173
Operating Income	215	-18	-421	-724	-360	-481	-200
Net Income	1,064	833	-295	-710	-408	-608	-181
EPS	17.72	13.92	-5.16	-13.05	-7.99	-13.40	-4.69
Growth Rates
Total Revenue Growth	83.2%	78.6%	198.6%	-17.4%	1105.7%	-47.4%	219.3%
EBITDA Growth	221.1%	154.7%	69.1%	-58.6%	34.6%	-246.7%	-86.3%
Operating Income Growth	152.6%	95.8%	41.9%	-101.1%	25.1%	-140.2%	-113.7%
Net Income Growth	424.6%	382.3%	58.4%	-73.8%	32.9%	-235.8%	-137.7%
Margins
EBITDA Margin	14.1%	4.8%	-15.7%	-151.6%	-79.0%	-1457.3%	-220.9%
Operating Income Margin	8.3%	-0.8%	-34.3%	-176.2%	-72.4%	-1165.2%	-255.0%
Net Income Margin	41.2%	38.0%	-24.1%	-172.8%	-82.1%	-1475.3%	-231.0%
Cash & Debt
Total Cash	�	3,379	3,180	2,193	2,337	1,996	1,501
Total Debt	0	39	20	12	11	10	7
Net Debt / (Cash)	�	-3,340	-3,160	-2,180	-2,325	-1,987	-1,493
Cash Flows
Net Cash from Operations	-	-83	-420	-863	-607	-398	152
Free Cash from Operations	-	-151	-464	-967	-728	-404	105
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Period End	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Filing Date	5/8/2025	3/20/2025	10/31/2024	7/25/2024	5/9/2024	3/21/2024	10/31/2023	7/27/2023	5/5/2023	3/16/2023	10/27/2022	7/28/2022
Key Financials Quarterly
Total Revenue	791	738	573	478	401	407	330	271	219	174	138	75
Ebitda	203	87	89	-14	-74	-61	-83	-84	-76	-42	-240	-216
Operating Income	141	102	16	-44	-92	-137	-80	-100	-103	-118	-209	-175
Net Income	169	774	91	29	-62	-99	-73	-94	-29	-39	-235	-209
EPS	2.78	12.93	1.52	0.49	-1.04	-1.69	-1.25	-1.69	-0.52	-0.70	-4.26	-3.80
Key Financials TTM
Total Revenue TTM	2,580	2,190	1,859	1,615	1,408	1,226	994	802	606	411	263	125
Ebitda TTM	365	88	-60	-232	-301	-304	-285	-442	-574	-727	-932	-922
Operating Income TTM	215	-18	-256	-352	-409	-421	-402	-531	-605	-724	-848	-852
Net Income TTM	1,064	833	-40	-204	-328	-295	-234	-397	-511	-710	-909	-907
Growth Rates Quarterly
Total Revenue Growth	97.2%	81.5%	73.8%	76.5%	83.0%	133.6%	139.0%	259.8%	836.0%	569.3%	16000.5%	-75.9%
EBITDA Growth	375.6%	243.2%	206.8%	82.7%	2.8%	-45.1%	65.4%	61.2%	66.8%	83.0%	-4.6%	-302.7%
Operating Income Growth	254.2%	174.2%	120.2%	56.3%	11.5%	-16.0%	61.7%	42.4%	53.5%	51.2%	2.0%	-283.5%
Net Income Growth	375.1%	880.6%	225.8%	130.8%	-113.4%	-156.8%	69.1%	54.8%	87.3%	83.8%	-0.6%	-301.5%
Margins Quarterly
EBITDA Margin	25.7%	11.8%	15.5%	-3.0%	-18.4%	-15.0%	-25.2%	-30.9%	-34.7%	-24.1%	-174.1%	-287.0%
Operating Income Margin	17.9%	13.8%	2.8%	-9.2%	-22.9%	-33.6%	-24.2%	-37.1%	-47.2%	-67.8%	-151.2%	-232.1%
Net Income Margin	21.4%	104.8%	15.9%	6.1%	-15.4%	-24.4%	-22.0%	-34.9%	-13.2%	-22.2%	-170.3%	-277.6%
Cash & Debt
Total Cash	-	3,379	-	3,102	-	3,180	-	1,997	-	2,193	-	2,597
Total Debt	0	39	0	34	0	20	0	11	0	12	0	10
Net Debt / (Cash)	-	-3,340	-	-3,068	-	-3,160	-	-1,986	-	-2,180	-	-2,588
Cash Flows Quarterly
FCF from Operations	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows TTM
FCF from Operations TTM	-	-	-	-	-	-	-	-	-	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-	10.9%	-	-4.8%	-	-16.4%	-	-12.9%	-	-16.1%	-	-30.3%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-0.5%	-	-8.5%	-	-12.2%	-	-15.3%	-	-25.7%	-	-37.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Single Segment	1,226	411	497	41	78
Total	1,226	411	497	41	78

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$722.01
Market Cap ($ Bil)	44.1
First Trading Date	05/18/2017
Distance from 52W High	0.0%
	50 Days	200 Days
DMA Price	$618.01	$610.87
DMA Trend	up	up
Distance from DMA	16.8%	18.2%
	3M	1YR
Volatility	36.1%	34.3%
Downside Capture	-35.03	29.88
Upside Capture	104.57	58.53
Correlation (SPY)	5.9%	24.2%
	5D	10D
Expected Return	2.9%	4.6%
Expected Excess Return	1.7%	6.3%
Chance of Rise	52.2%	54.5%
Std Dev of Returns	2.1%	2.8%

ARGX Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.16	-0.02	0.14	0.48	0.42	0.59
Up Beta	-0.35	-0.55	-0.22	0.27	0.26	0.49
Down Beta	-0.43	-0.70	-0.16	0.62	0.63	0.73
Up Capture	85%	180%	92%	65%	44%	32%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	11	26	33	65	129	381
Down Capture	-1%	-133%	-43%	64%	38%	81%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	10	15	29	60	119	368

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	1,805,466
Short Interest: % Change Since 7312025	-4.0%
Average Daily Volume	433,284
Days-to-Cover Short Interest	4.17
Basic Shares Quantity	60,983,325
Short % of Basic Shares	3.0%

SEC Filings

Expand for More

Report Date	Filing
6302025	6-K 6/30/2025
3312025	6-K 3/31/2025
12312024	20-F 12/31/2024
9302024	6-K 9/30/2024
6302024	6-K 6/30/2024
3312024	6-K 3/31/2024
12312023	20-F 12/31/2023
9302023	6-K 9/30/2023
6302023	6-K 6/30/2023
3312023	6-K 3/31/2023
12312022	20-F 12/31/2022
9302022	6-K 9/30/2022
6302022	6-K 6/30/2022
3312022	6-K 3/31/2022
12312021	20-F 12/31/2021
6302021	6-K 6/30/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ARGX Return	83%	19%	8%	0%	62%	17%	320%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%
Monthly Win Rates [3]
ARGX Win Rate	67%	50%	58%	50%	67%	43%
Peers Win Rate	55%	55%	55%	53%	57%	63%
S&P 500 Win Rate	58%	75%	42%	67%	75%	57%
Max Drawdowns [4]
ARGX Max Drawdown	-32%	-13%	-27%	-12%	-6%	-13%
Peers Max Drawdown	-16%	-9%	-7%	-11%	-11%	-10%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

argenx (ARGX)

Market Price (9/4/2025): $720.99 | Market Cap: $44.0 BilSector: Health Care | Industry: Biotechnology

argenx (ARGX)

Market Price (9/4/2025): $720.99Market Cap: $44.0 BilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than argenx (ARGX)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for argenx

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $720.99 | Market Cap: $44.0 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (9/4/2025): $720.99
Market Cap: $44.0 Bil
Sector: Health Care
Industry: Biotechnology